The research methodology involved searching through seven different databases, including Pubmed, four Korean and one Chinese, for randomized animal studies published up until April 2015. The studies must have investigated the effects of GMDZ decoction on neuropsychiatric disorders to qualify for inclusion. Double-blind reviews were done on all qualifying paper, leading to the selection of six randomized controlled animal studies. These were studies that used a Sprague Dawley rat model for acute psychological stress, post-traumatic stress disorders, and unpredictable mild stress depression, or a Kunming mouse model for prenatal depression.

The results showed consistent improvements in neuropsychiatric disease-related outcomes across the variety of animal models, demonstrating GMDZ decoction's significance in enhancing these results. This effect was independent of the decoction's dose or concentration. Whether the focus was on acute psychological stress, post-traumatic stress disorders, unpredictable mild stress depression or prenatal depression, GMDZ consistently demonstrated a potential for effective therapeutic application in managing neuropsychiatric diseases.